In a phase I trial (NCT01148849), 66 patients with HER2-overexpressing advanced BC received intravenous infusion of MGAH22, which was well tolerated, and partial responses and stable disease were observed in 12% and 50% of patients, respectively; also tumor reduction was observed in over half (18/23, 78%) of response-evaluable patients with BC [110]. The gene discussed is ERBB2; the disease is breast cancer.